Maxim Group Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $3
Maxim Group Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Cuts Target Price to $3
Lineage Cell Therapeutics Analyst Ratings
D. Boral Capital Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Cuts Target Price to $2
Lineage Cell Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Lineage Cell Therapeutics Price Target Announced at $3.00/Share by D. Boral Capital
Lineage Cell Therapeutics Analyst Ratings
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Announces Target Price $4
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating
Craig-Hallum Initiates Lineage Cell Therapeutics(LCTX.US) With Buy Rating
Baird Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $5
Craig-Hallum Initiates Lineage Cell Therapeutics at Buy With $4 Price Target
Lineage Cell Therapeutics Analyst Ratings
Craig-Hallum Initiates Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Announces Target Price $4
Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline Progress
Lineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical Progress
B.Riley Financial Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Lineage Cell Therapeutics on Promising OpRegen Trials and Strategic Roche Partnership